Lessons from treatment algorithms developed for patients with more common oncogenic drivers in NSCLC, such as EGFR mutations and ALK fusions, will guide and inform the optimal approach to patients in rarer fusion subsets. The gene discussed is ALK; the disease is non-small cell lung carcinoma.